Cantor Fitzgerald Sticks to Its Hold Rating for Amedisys (AMED)

In a report released today, Joseph France from Cantor Fitzgerald maintained a Hold rating on Amedisys (NASDAQ: AMED), with a price target of $117. The company’s shares closed yesterday at $118.86, close to its 52-week high of $127.38.

France observed:

“We have a Neutral rating on AMED and a 12-month price target of $117. The company’s M&A strategy is currently focused on hospice and personal care, and we believe that the continued interest in hospice assets by private equity, and various industry tailwinds will support the somewhat boosted valuation in the name. We like AMED’s management, clinical focus and strong capital position, but valuations look rich at 21.4x EBITDA, and we see little room for upside.”

According to, France is a 5-star analyst with an average return of 10.9% and a 59.8% success rate. France covers the Services sector, focusing on stocks such as Cross Country Healthcare, Five Star Quality Care, and Addus Homecare Corp.

Amedisys has an analyst consensus of Moderate Buy, with a price target consensus of $118.63.

See today’s analyst top recommended stocks >>

Amedisys’ market cap is currently $3.78B and has a P/E ratio of 57.14. The company has a Price to Book ratio of 9.27.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.

From Our Partners